Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Km04

Phase 1

Km04 is one of 17 therapeutic programs targeting Female. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

16

Competitors

Pipeline

Status by Indication[2][1]

Indication

FemaleNot yet recruiting

FemalePhase 1

Not yet recruiting

Competition

Competitive Landscape

19 competitors in Female

#DrugCompanyPhaseTrials

Activella

Dostarlimab

Jemperli

GGlaxo Dba Glaxosmithkline

Versed

CConrado Roberto Hoffmann Filho

Faslodex

FFresenius Kabi USA, LLC

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

MK-8527

Telpegfilgrastim

XXiamen Amoytop Biotech Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Study completion

NCT07794683

Clinical

Trials by Indication[1]

Unspecified1 trial

A Single Center, Single-Dose, Double-Blind, Randomized, Three-Treatment, Three-Period, Six-Sequence, Crossover Study to Demonstrate Pharmacokinetic Similarity Between KM04, US-Gonal-f® RFF Redi-ject®, EU-Gonal-f®, and to Evaluate Safety in Healthy Adult Female Volunteers

Not yet recruiting·XXentria, Inc.·Phase 1·NCT07794683·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Km04. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Km04. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xentria, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: XXentria, Inc.

Related News